Literature DB >> 16847029

Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.

Paul G Mariani, Helio S Sader, Ronald N Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847029     DOI: 10.1093/jac/dkl256

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  22 in total

1.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 2.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

3.  Impact of Bacterial Membrane Fatty Acid Composition on the Failure of Daptomycin To Kill Staphylococcus aureus.

Authors:  Rym Boudjemaa; Clément Cabriel; Florence Dubois-Brissonnet; Nicolas Bourg; Guillaume Dupuis; Alexandra Gruss; Sandrine Lévêque-Fort; Romain Briandet; Marie-Pierre Fontaine-Aupart; Karine Steenkeste
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections.

Authors:  Noreen H Chan Tompkins; Stephen J Harnicar
Journal:  P T       Date:  2008-05

5.  Striking "seesaw effect" between daptomycin nonsusceptibility and beta-lactam susceptibility in Staphylococcus haemolyticus.

Authors:  Carla Vignaroli; Caterina Rinaldi; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2011-05       Impact factor: 5.191

6.  The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus.

Authors:  Wei Gao; David R Cameron; John K Davies; Xenia Kostoulias; Justin Stepnell; Kellie L Tuck; Michael R Yeaman; Anton Y Peleg; Timothy P Stinear; Benjamin P Howden
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

7.  Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").

Authors:  Soo-Jin Yang; Yan Q Xiong; Susan Boyle-Vavra; Robert Daum; Tiffanny Jones; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

8.  Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance.

Authors:  Soo-Jin Yang; Nagendra N Mishra; Aileen Rubio; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

Review 9.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.